<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="165">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070884</url>
  </required_header>
  <id_info>
    <org_study_id>RADIOVAL</org_study_id>
    <nct_id>NCT05070884</nct_id>
  </id_info>
  <brief_title>Clinical Validation of Radiomics Artificial Intelligence: Application to Breast Cancer Treatment Planning</brief_title>
  <acronym>RADIOVAL</acronym>
  <official_title>Clinical Validation of Radiomics Artificial Intelligence: Application to Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigacion Sanitaria La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical School University of Zagreb</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hacettepe University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alexander Fleming Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigacion Sanitaria La Fe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RadioVal will develop and implement interoperable solutions for clinical deployment of the&#xD;
      radiomics tools, including information, training, and communication packages for clinicians&#xD;
      and patients, as well as standard operating procedures for the integration of radiomics in&#xD;
      clinical oncology. With this study, we will clinically validate these solutions, by looking&#xD;
      at their reliability for precise breast cancer diagnosis, treatment recommendation and&#xD;
      prognosis estimate, treatment response, evaluation of residual disease and outcome&#xD;
      prediction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2023</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients non-respondents vs respondents in neoadjuvant breast cancer treatment (Estimate tumor aggressiveness)</measure>
    <time_frame>Baseline and after neoadjuvant treatment (4-6 months)</time_frame>
    <description>Proportion of patients who have complete response evaluating the target lesion according to Miller/Payne Grading system [Ogston et al., 2003]: 1A. Evaluation of target Tumor: G5 as pathological complete response, no tumor left; G4:more than 90% loss of tumor cells; G3: between 30-90% reduction in tumor cells; G2: loss of tumor &lt;30%; G1: no reduction. 1B: Evaluating the lymph nodes: A: negative; B: lymph nodes with metastasis and without changes by chemotherapy; C: lymph nodes with metastasis with evidence of partial response, D: lymph nodes with changes attributed to response without residual infiltration. 1C: Using images to evaluated radiological response: Size and diameter in millimeters of the target lesion using RM and TC or PET/CT for extension analysis (lymph nodes and metastasis).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>non respondants of neo treatment</arm_group_label>
    <description>those patients with no response or partial response when administered with Chemotherapy prior to sugery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>The development of new clinical AI solutions to predict treatment response to neoadjuvant chemotherapy (NAC) in breast cancer</intervention_name>
    <description>Evaluate response to neoadjuvant treatment in advanced breast cancer</description>
    <arm_group_label>non respondants of neo treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with chemotherapy prior to surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females â‰¥ 18 years up to 85 years old&#xD;
&#xD;
          -  Individuals referred to hospitals for diagnosis of breast cancer&#xD;
&#xD;
          -  Availability of radiological images: 2D mammography or 2D synthetic digital&#xD;
             tomosynthesis, ultrasound, or magnetic resonance&#xD;
&#xD;
          -  Availability of pathological report (surgical specimen)&#xD;
&#xD;
          -  Availability of (Neoadjuvant) treatment allocation (scheme, duration, benefit)&#xD;
&#xD;
          -  Availability of treatment response&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with incomplete or low-quality data (radiological, pathological or clinical)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ana Penades-Blasco, M.Ec</last_name>
    <phone>+34 961245633</phone>
    <email>ana_penades@iislafe.es</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>N/D</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

